1.62
price up icon5.19%   0.08
after-market Handel nachbörslich: 1.54 -0.08 -4.94%
loading
Schlusskurs vom Vortag:
$1.54
Offen:
$1.56
24-Stunden-Volumen:
441.40K
Relative Volume:
0.37
Marktkapitalisierung:
$97.52M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-73.79M
KGV:
-0.8804
EPS:
-1.84
Netto-Cashflow:
$-77.44M
1W Leistung:
-1.22%
1M Leistung:
+3.85%
6M Leistung:
-57.92%
1J Leistung:
-59.80%
1-Tages-Spanne:
Value
$1.56
$1.66
1-Wochen-Bereich:
Value
$1.5005
$1.67
52-Wochen-Spanne:
Value
$1.39
$6.85

Pyxis Oncology Inc Stock (PYXS) Company Profile

Name
Firmenname
Pyxis Oncology Inc
Name
Telefon
(617) 221-9059
Name
Adresse
321 HARRISON AVENUE, BOSTON
Name
Mitarbeiter
54
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-11
Name
Neueste SEC-Einreichungen
Name
PYXS's Discussions on Twitter

Vergleichen Sie PYXS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PYXS
Pyxis Oncology Inc
1.62 97.52M 0 -73.79M -77.44M -1.84
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
438.40 113.67B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
683.08 74.97B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
665.68 40.50B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
277.16 35.95B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
120.88 29.63B 3.30B -501.07M 1.03B -2.1146

Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-11-21 Herabstufung William Blair Outperform → Mkt Perform
2024-11-08 Eingeleitet Stephens Overweight
2024-08-08 Eingeleitet Stifel Buy
2024-05-07 Fortgesetzt Jefferies Buy
2024-02-09 Eingeleitet BTIG Research Buy
2024-01-23 Eingeleitet Leerink Partners Outperform
2023-09-05 Eingeleitet RBC Capital Mkts Outperform
2021-11-02 Eingeleitet BofA Securities Neutral
2021-11-02 Eingeleitet Credit Suisse Outperform
2021-11-02 Eingeleitet Jefferies Buy
Alle ansehen

Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten

pulisher
Jan 21, 2025

Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset - MSN

Jan 21, 2025
pulisher
Jan 21, 2025

Barclays PLC Purchases 46,997 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World

Jan 21, 2025
pulisher
Jan 14, 2025

Pyxis Oncology, Inc. (NASDAQ:PYXS) Holdings Raised by Jane Street Group LLC - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

Pyxis Oncology stock hits 52-week low at $1.49 By Investing.com - Investing.com South Africa

Jan 13, 2025
pulisher
Jan 13, 2025

Pyxis Oncology stock hits 52-week low at $1.49 - Investing.com India

Jan 13, 2025
pulisher
Jan 07, 2025

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Jan 07, 2025
pulisher
Jan 07, 2025

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.43 Average Price Target from Analysts - MarketBeat

Jan 07, 2025
pulisher
Jan 06, 2025

Pyxis Oncology, Inc. (NASDAQ:PYXS) Stock Position Raised by Geode Capital Management LLC - Defense World

Jan 06, 2025
pulisher
Jan 06, 2025

Barclays PLC Increases Stock Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World

Jan 06, 2025
pulisher
Dec 31, 2024

State Street Corp Buys 208,344 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World

Dec 31, 2024
pulisher
Dec 30, 2024

Pick Pyxis in head and neck despite pullback on ADC phase I? - BioWorld Online

Dec 30, 2024
pulisher
Dec 24, 2024

Pyxis Oncology stock outlook adjusted with focus on ADC program and cost management - Investing.com Nigeria

Dec 24, 2024
pulisher
Dec 23, 2024

Pyxis Oncology stock outlook adjusted with focus on ADC program and cost management By Investing.com - Investing.com South Africa

Dec 23, 2024
pulisher
Dec 23, 2024

Pyxis Oncology’s (PYXS) “Outperform” Rating Reiterated at Royal Bank of Canada - Defense World

Dec 23, 2024
pulisher
Dec 21, 2024

Pyxis Oncology price target lowered to $8 from $10 at RBC Capital - Yahoo Finance

Dec 21, 2024
pulisher
Dec 20, 2024

Pyxis Oncology shares target cut, outperform rating on pipeline update By Investing.com - Investing.com Australia

Dec 20, 2024
pulisher
Dec 20, 2024

Pyxis Oncology shares target cut, outperform rating on pipeline update - Investing.com

Dec 20, 2024
pulisher
Dec 20, 2024

Pyxis Oncology's (PYXS) Buy Rating Reiterated at HC Wainwright - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move - Benzinga

Dec 20, 2024
pulisher
Dec 20, 2024

Royal Bank of Canada Reaffirms Outperform Rating for Pyxis Oncology (NASDAQ:PYXS) - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Pyxis Oncology advances lead cancer drug PYX-201 By Investing.com - Investing.com Canada

Dec 20, 2024
pulisher
Dec 19, 2024

Pyxis Oncology to Focus on PYX-201, Suspends PYX-106 Program - MarketWatch

Dec 19, 2024
pulisher
Dec 19, 2024

Pyxis Oncology advances lead cancer drug PYX-201 - Investing.com

Dec 19, 2024
pulisher
Dec 19, 2024

Pyxis Oncology to prioritize PYX-201, suspends investment in PYX-106 - TipRanks

Dec 19, 2024
pulisher
Dec 19, 2024

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 - The Manila Times

Dec 19, 2024
pulisher
Dec 19, 2024

Pyxis Oncology, Inc. Announces Portfolio Prioritization, Focusing Resources on Its Lead Clinical Program, PYX-201 - Marketscreener.com

Dec 19, 2024
pulisher
Dec 19, 2024

Pyxis Oncology stock hits 52-week low at $1.5 amid market challenges - Investing.com Canada

Dec 19, 2024
pulisher
Dec 15, 2024

Pyxis Oncology's SWOT analysis: ADC developer's stock shows promise amid trials - Investing.com Canada

Dec 15, 2024
pulisher
Dec 13, 2024

Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Dec 13, 2024
pulisher
Dec 13, 2024

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $10.00 Average Price Target from Brokerages - MarketBeat

Dec 13, 2024
pulisher
Dec 11, 2024

Pyxis Oncology stock hits 52-week low at $1.64 - Investing.com

Dec 11, 2024
pulisher
Dec 11, 2024

Pyxis Oncology stock hits 52-week low at $1.64 By Investing.com - Investing.com UK

Dec 11, 2024
pulisher
Dec 09, 2024

Jacobs Levy Equity Management Inc. Makes New Investment in Pyxis Oncology, Inc. (NASDAQ:PYXS) - MarketBeat

Dec 09, 2024
pulisher
Dec 09, 2024

14,897 Shares in Pyxis Oncology, Inc. (NASDAQ:PYXS) Bought by Intech Investment Management LLC - Defense World

Dec 09, 2024
pulisher
Dec 07, 2024

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead (NASDAQ:PYXS) - Seeking Alpha

Dec 07, 2024
pulisher
Dec 01, 2024

CFO & COO of Pyxis Oncology Pamela Connealy Buys 13% More Shares - Yahoo Finance

Dec 01, 2024
pulisher
Nov 28, 2024

Pyxis Oncology CFO acquires shares worth $174,364 - Investing.com India

Nov 28, 2024
pulisher
Nov 28, 2024

Pyxis Oncology CFO acquires shares worth $174,364 By Investing.com - Investing.com South Africa

Nov 28, 2024
pulisher
Nov 27, 2024

Institutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$142m market cap decline as longer-term profits stay in the green - Yahoo Finance

Nov 27, 2024
pulisher
Nov 26, 2024

Pressure on Pyxis despite promising PYX-201 data - The Pharma Letter

Nov 26, 2024
pulisher
Nov 25, 2024

Pyxis Oncology's SWOT analysis: ADC innovator's stock poised for growth - Investing.com

Nov 25, 2024
pulisher
Nov 25, 2024

Pyxis Oncology's SWOT analysis: ADC innovator's stock poised for growth By Investing.com - Investing.com UK

Nov 25, 2024

Finanzdaten der Pyxis Oncology Inc-Aktie (PYXS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$352.30
price down icon 5.49%
$41.04
price up icon 0.79%
$22.36
price up icon 3.33%
$5.41
price up icon 3.84%
biotechnology ONC
$226.89
price up icon 0.08%
$120.88
price down icon 0.23%
Kapitalisierung:     |  Volumen (24h):